-
公开(公告)号:EP3872177A1
公开(公告)日:2021-09-01
申请号:EP20213966.3
申请日:2017-05-25
Applicant: Life Technologies Corporation
Inventor: LIANG, Xiquan , POTTER, Robert , RAVINDER, Namritha , KUMAR, Shantanu
Abstract: The present disclosure generally relates to compositions and methods for improving the efficiency of homologous recombination. In particular, the disclosure relates to reagents and the use of such reagents.
-
公开(公告)号:EP3204513A2
公开(公告)日:2017-08-16
申请号:EP15785207.0
申请日:2015-10-09
Inventor: RAVINDER, Namritha , HEIL, Korbinian , GUO, Yizhu , LIANG, Xiquan , POTTER, Robert
IPC: C12Q1/68 , C12N15/113 , C12N15/10
CPC classification number: C12N15/907 , C12N15/102 , C12N15/11 , C12N2310/3519 , C12P19/34 , C12Q1/686 , C12Q2525/143
Abstract: The present disclosure generally relates to compositions and methods for the genetic modification of cells. In particular, the disclosure relates to CRISPR reagents and the use of such reagents.
Abstract translation: 本公开总体上涉及用于细胞遗传修饰的组合物和方法。 特别地,本公开涉及CRISPR试剂和这些试剂的用途。
-
公开(公告)号:EP4401757A1
公开(公告)日:2024-07-24
申请号:EP22800037.8
申请日:2022-09-13
Applicant: Life Technologies Corporation
Inventor: CHESNUT, Jonathan , IHLAN, Alicia , POTTER, Robert , SONG, Youngzee
CPC classification number: C12N9/22 , C12N15/907 , C07K2319/8020130101 , A61K38/00 , C07K2319/8120130101
-
公开(公告)号:EP4175967A2
公开(公告)日:2023-05-10
申请号:EP21746278.7
申请日:2021-07-01
Applicant: Life Technologies Corporation
-
公开(公告)号:EP4114972A1
公开(公告)日:2023-01-11
申请号:EP21714586.1
申请日:2021-03-05
Inventor: POTTER, Robert , NETUSCHIL, Nikolai
-
公开(公告)号:EP3679143A1
公开(公告)日:2020-07-15
申请号:EP18779883.0
申请日:2018-09-07
Applicant: Life Technologies Corporation
Inventor: LIANG, Xiquan , POTTER, Robert , PENG, Lansha
IPC: C12N15/63
-
公开(公告)号:EP3998344A1
公开(公告)日:2022-05-18
申请号:EP21198861.3
申请日:2015-10-09
Inventor: RAVINDER, Namritha , HEIL, Korbinian , GUO, Yizhu , LIANG, Xiquan , POTTER, Robert
IPC: C12Q1/68 , C12N15/113 , C12N15/10 , C12N15/90
Abstract: The present disclosure generally relates to compositions and methods for the genetic modification of cells. In particular, the disclosure relates to CRISPR reagents and the use of such reagents.
-
-
-
-
-
-